BMY—Someone on Twitter asked (perhaps rhetorically) why this Opdivo/Yervoy sBLA is not getting an FDA priority review. Well, the TMB assays are still being tweaked, so perhaps speeding up this review by four months wouldn't be a good idea.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.